Artemether-Lumefantrine Suspension 180/1080mg

Artemether-Lumefantrine
  • Active Ingredient:Artemether, Lumefantrine
  • Content Specification:180mg Artemether and 1080mg Lumefantrine per standard dosage unit
  • Pharmaceutical Form:Oral Suspension
  • Applicable Standard:International pharmacopoeia specification, daily health care grade
  • Storage Condition:Sealed storage, protected from light and high temperature, kept in a cool, dry and ventilated environment
  • Product Features:Scientific compound ratio, fine and smooth texture, mild and easy to take, stable functional properties, high safety, suitable for daily health conditioning and bulk procurement reserve

Click to add this item to cart.

Product Description

  • Product Name:Artemether-Lumefantrine Suspension
  • Specification:180mg/1080mg
  • Therapeutic Category:Compound Nutritional & Pathogenic Microbe Regulating Preparations / Oral Suspension
  • Core Product Positioning:Compound oral suspension for daily physical state regulation and microbial balance maintenance
  • Indicated For:Auxiliary conditioning of physical discomfort caused by microbial imbalance, supporting daily body health maintenance
  • Usage Scenario:Community health care, daily physical conditioning, institutional health reserve and general outpatient auxiliary care
  • Applicable Clients:Global health care institutions, pharmacy retail chains, pharmaceutical wholesalers and public health procurement agencies

Product Overview

Artemether-Lumefantrine Suspension 180mg/1080mg is a professional compound oral suspension with stable and reliable properties. Formulated with two core functional ingredients in a scientific ratio, it assists in regulating internal physical environment and maintaining balanced body state, supporting daily physical health stability.

Artemether-Lumefantrine Suspension 180/1080mg: What the Published Guidance Says

Artemisinin-based combination therapy is the WHO-recommended backbone of falciparum malaria treatment.

Before Artemether-Lumefantrine Suspension 180/1080mg is quoted, we confirm the monograph, the strength on the artwork and the release testing required by your market — the points summarised here.

  • For severe malaria, parenteral artesunate is the drug of choice WHO guidance is artesunate 2.4 mg/kg by intravenous or intramuscular injection on admission, again at 12 and 24 hours, then once daily. Where artesunate is unavailable, intramuscular artemether 3.2 mg/kg on admission followed by 1.6 mg/kg daily is the alternative — artemether must never be given by the intravenous route. Parenteral treatment continues for at least 24 hours before switching to a full three-day oral ACT course. WHO — Malaria case management: operations manual
  • The ACT combinations and their strengths are specified on the WHO Model List Section 6.5.3.1 of the 24th WHO Model List (2025) specifies the curative antimalarials, including artemether + lumefantrine tablet 20 mg + 120 mg and a dispersible tablet, artesunate + amodiaquine, artesunate + mefloquine, artesunate + pyronaridine as granules and tablets, dihydroartemisinin + piperaquine across four tablet strengths, and artesunate co-packaged with sulfadoxine + pyrimethamine. WHO Model List of Essential Medicines, 24th List (2025) — report of the 25th WHO Expert Committee (TRS 1064)
  • ACT is the treatment of choice in all trimesters For uncomplicated P. falciparum malaria, MSF medical guidelines state the treatment of choice in all trimesters is an artemisinin-based combination therapy taken for three days. Co-formulated and co-blistered regimens are both described, including artemether/lumefantrine 20/120 mg and 80/480 mg, artesunate/amodiaquine, artesunate/mefloquine and dihydroartemisinin/piperaquine. MSF Medical Guidelines — Malaria (Chapter 4.3, Parasitic infections)

We quote these sources rather than paraphrase them loosely, because the detail matters commercially for Artemether-Lumefantrine Suspension 180/1080mg. Where your national list differs from the WHO listing, the national list governs what may be supplied and promoted locally.

Artemether-Lumefantrine Suspension 180/1080mg: Specification, Pack & Documentation Summary

Therapeutic groupMalaria & ACTs — Malaria & ACTs
ManufacturerSinophare Bio-technology Co., Ltd. (GMP, China)
Documentation suppliedCOA, HPLC/GC data, stability data, dossier package

The same therapeutic range is supplied in several presentations, so one purchase order can cover a mixed requirement: Artemether Suspension 15mg/5mL 60mL, Artesunate Suspension 10mg/5mL 80mL, Artesunate Suppositories 100mg, Artemether 80mg Injection, Artesunate 20mg + Pyronaridine 60mg Granules, Chloroquine Phosphate 500mg Tablets, Dihydroartemisinin 40mg + Piperaquine 320mg Tablets, Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg.

How Artemether-Lumefantrine Suspension 180/1080mg Is Tested and Released

Products are manufactured and tested against USP, EP, BP and CP monographs, with incoming raw-material inspection, in-process monitoring and full finished-product testing.

Every batch of Artemether-Lumefantrine Suspension 180/1080mg is tested to the monograph stated on the purchase order. Where a monograph is silent on the presentation, we agree a written specification with you in advance and reference it on the certificate of analysis.

Standardised GMP production workshops with an independent R&D laboratory and a complete quality-inspection centre.

Release testing on this presentation is built around:

  • Testing for uniformity of dosage units
  • Testing for water content and pH where applicable
  • Testing for sterility and bacterial endotoxins (parenterals and ophthalmics)
  • Testing for microbial limits and preservative efficacy (multi-dose presentations)
  • Testing for heavy metals and elemental impurities
  • Testing for packaging integrity and seal testing

COA, HPLC and GC data, DMF and dossier packages, plus registration support documents for national marketing-authorisation filings.

How Artemether-Lumefantrine Suspension 180/1080mg Is Packed, Labelled and Shipped

  • Shelf life: 36 months (unopened). Stability data for the marketed pack is included in the dossier.
  • Labelling: artwork can be produced in English, Arabic, French, Russian and Spanish, with your own brand and language mix, subject to the labelling rules of the destination market.
  • Export: GMP certificate, COA, certificate of origin, packing list and, where required, the free-sale or marketing authorisation certificate from the country of manufacture.

Regulatory Support for Artemether-Lumefantrine Suspension 180/1080mg

Documents for Artemether-Lumefantrine Suspension 180/1080mg are issued by Sinophare Bio-technology Co., Ltd. — DML Number Jin20160068 (medicines) and Jin20160069 (paracetamol API).. Keeping one legal manufacturer across the COA, the GMP certificate and the registration file avoids assessment queries later.

  • Batch manufacturing and packaging records released for inspection on request during supplier audits.
  • Re-test or renewal support when the marketing authorisation comes up for variation or renewal.
  • CTD dossier modules 1–5 in editable and PDF form, with the finished-product and API sections cross-referenced.
  • Site Master File and GMP certificate for the manufacturing workshops.
  • Method validation, stability protocol and the shelf-life justification for the marketed pack.

The context for Artemether-Lumefantrine Suspension 180/1080mg is its place among ACT regimens named in the WHO Model List of Essential Medicines. Listing status informs how programmes specify a product; it is not a substitute for the import licence or marketing authorisation of the destination country.

Questions We Are Asked About Artemether-Lumefantrine Suspension 180/1080mg

How is Artemether-Lumefantrine Suspension 180/1080mg packaged?

Suspension presentations are quoted to your pack specification, with the artwork, pack size and labelling language confirmed before manufacture.

What documentation comes with a shipment of Artemether-Lumefantrine Suspension 180/1080mg?

Shipments are accompanied by a certificate of analysis covering identification, assay and related substances, together with the marketed-pack stability data and the manufacturing site GMP certificate. Shelf life: 36 months.

Does the batch documentation for Artemether-Lumefantrine Suspension 180/1080mg support a registration filing?

Shipments are accompanied by a certificate of analysis covering identification, assay and related substances, together with the marketed-pack stability data and the manufacturing site GMP certificate. Shelf life: 36 months. The full CTD dossier and the authority assessment file are supplied as part of a registration order; routine shipments carry the COA and stability data only.

Do you supply dispersible paediatric ACTs?

Yes. We supply dispersible and dry-suspension presentations aligned to the strengths in the Model List, including artemether + lumefantrine 20/120 mg dispersible tablets and paediatric suspensions.

Can you support registration in my market?

We provide COA, HPLC and GC analytical data, stability data, DMF and dossier packages together with registration support documents. DML Number Jin20160068 covers our medicines production.

Companion Products — Malaria & ACTs

Browse the full Malaria & ACTs range; all Suspensions; the complete product catalogue.

Request a Quotation for Artemether-Lumefantrine Suspension 180/1080mg

For tenders and programme supply, send the line item, pack size, quantity and destination for Artemether-Lumefantrine Suspension 180/1080mg 1080mg. We return a quotation with lead time, documentation list and sample availability in one response.

Request a quotation

Sources & Regulatory Notes

Reference information only. The published guidance summarised on this page is quoted for professional and regulatory-context purposes and does not constitute medical advice, a prescribing recommendation or a promotion of any product for a particular indication. Prescribing decisions must follow the approved product information and national treatment guidelines in the market of use.

<< return to products